Literature DB >> 31564708

Changes in Gut Microbiome Structure and Function of Rats with Isoproterenol-Induced Heart Failure.

Ancai Zheng1,2, Hong Yi1, Fan Li1, Lu Han1, Jianhua Yu1, Xiaoshu Cheng1, Hai Su1, Kui Hong1, Juxiang Li1.   

Abstract

Recently, the potential role of gut microbiome (GM) in cardiovascular diseases has been revealed. Heart failure (HF) is one of the most prevalent cardiovascular diseases worldwide; however, whether GM dysbiosis participates in the development of HF remains largely unknown. This study aimed to investigate the specific changes in GM composition and function in isoproterenol (ISO)-induced HF in rats.The rats were divided into C (control), 4w-HF (ISO, 2.5 mg/kg/day for 4 weeks, intraperitoneally), and 2w-HF (ISO, 2.5 mg/kg/day for 2 weeks, intraperitoneally) groups. The cardiac structure and function in rats were assessed, and metagenomic analyses were then performed. Compared with the healthy control group, we found that the Shannon diversity index and microbial gene count in the 4w-HF and 2w-HF groups was drastically decreased. High-throughput sequencing showed that the three groups differed in intestinal bacterial community composition. Overgrowth of bacteria, such as Prevotella, was observed in the 4w-HF group, with reduced growth of bacteria, such as Roseburia, Lactobacillus, and Butyrivibrio, associated with healthy status compared with the C group on the genus level. Concomitant with the alteration of GM composition, underrepresentation of health-linked microbial function was observed in both the 4w-HF and 2w-HF groups compared with the C group.Iso-induced HF rats showed a significant decrease in the diversity and richness of the intestinal microbiome, with a downregulation of the key intestinal bacterial groups and overgrowth of bacteria considered to be involved in inflammatory responses as well as a decrease in health-linked microbial function. Our data indicated that altered GM may be a potential player in the pathogenesis and progression of HF.

Entities:  

Keywords:  Community composition; High-throughput sequencing; Inflammation

Mesh:

Substances:

Year:  2019        PMID: 31564708     DOI: 10.1536/ihj.18-194

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  6 in total

1.  Heart Failure Severity Closely Correlates with Intestinal Dysbiosis and Subsequent Metabolomic Alterations.

Authors:  Martina E Spehlmann; Ashraf Y Rangrez; Dhiraj P Dhotre; Nesrin Schmiedel; Nikita Chavan; Corinna Bang; Oliver J Müller; Yogesh S Shouche; Andre Franke; Derk Frank; Norbert Frey
Journal:  Biomedicines       Date:  2022-03-30

2.  Changes of gut microbiome composition and metabolites associated with hypertensive heart failure rats.

Authors:  Lin Li; Sen-Jie Zhong; Si-Yuan Hu; Bin Cheng; Hong Qiu; Zhi-Xi Hu
Journal:  BMC Microbiol       Date:  2021-05-05       Impact factor: 3.605

3.  Transverse aortic constriction induces gut barrier alterations, microbiota remodeling and systemic inflammation.

Authors:  Nicola Boccella; Roberta Paolillo; Lorena Coretti; Stefania D'Apice; Francesca Lembo; Cinzia Perrino; Adriano Lama; Giuseppe Giugliano; Gabriele Giacomo Schiattarella; Mariella Cuomo; Ilaria d'Aquino; Gina Cavaliere; Orlando Paciello; Maria Pina Mollica; Giuseppina Mattace Raso; Giovanni Esposito
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

4.  Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study).

Authors:  Ziyin Huang; Xiaofei Mei; Yufeng Jiang; Tan Chen; Yafeng Zhou
Journal:  Front Cardiovasc Med       Date:  2022-01-06

Review 5.  Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species.

Authors:  Kai Nie; Kejia Ma; Weiwei Luo; Zhaohua Shen; Zhenyu Yang; Mengwei Xiao; Ting Tong; Yuanyuan Yang; Xiaoyan Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-11-22       Impact factor: 5.293

6.  Effect of High-Fat Diet  on  the Intestinal Flora in Letrozole-Induced Polycystic Ovary Syndrome Rats.

Authors:  Yan-Hua Zheng; Ying Xu; Hong-Xia Ma; Cheng-Jie Liang; Tong Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-25       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.